Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04220021 · ClinicalTrials.gov registry record · Phase 2
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
A Phase 2 study of Frontotemporal Dementia and C9orf72 Amyotrophic Lateral Sclerosis (ALS), sponsored by University of Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT04220021 is a Phase 2 study of Frontotemporal Dementia and C9orf72 Amyotrophic Lateral Sclerosis (ALS) that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 41 participants, below the 1,196-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04220021, a Phase 2 study of Frontotemporal Dementia and C9orf72 Amyotrophic Lateral Sclerosis (ALS), is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to assess the safety and tolerability of Metformin in subjects with C9orf72 amyotrophic lateral sclerosis administered for 24 weeks. The overall objective is to determine if Metformin is safe in C9orf72 ALS patients and is a potentially viable therapeutic treatment for C9-ALS that reduces repeat-associated non-canonical start codon - in DNA (non-ATG) (RAN) proteins that are produced by the C9orf72 repeat expansion mutation.
Conditions Studied
Interventions
- DRUG Metformin
Study Locations (1)
Florida
- UF Health at the University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04220021
The ClinicalTrials.gov registry entry for NCT04220021 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,196-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (97% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Frontotemporal Dementia appearing as the primary indexed condition, and to 1 intervention - of which Metformin is the first listed.
NCT04220021 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04220021 about?
NCT04220021 is a clinical study titled "Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD". The primary objective is to assess the safety and tolerability of Metformin in subjects with C9orf72 amyotrophic lateral sclerosis administered for 24 weeks. The overall objective is to determine if Metformin is safe in C9orf72 ALS patients and is a potentially viable therapeutic treatment for C9-AL...
What is the current status of trial NCT04220021?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2020-01-10. Estimated completion is 2026-06-30.
What conditions does trial NCT04220021 study?
This clinical trial studies the following conditions: Frontotemporal Dementia, C9orf72 Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT04220021?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT04220021?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04220021 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Frontotemporal Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
RECRUITING · Phase 2
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Longitudinal Cognitive Assessment by BoCA
RECRUITING
-
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
RECRUITING · Phase 1
Explore more on PlainTrial
Frontotemporal Dementia
All registered trials for this condition
C9orf72 Amyotrophic Lateral Sclerosis (ALS)
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.